ArticleInternational journal of obesity (2005)2026
Weight loss and alcohol reduction synergize for hepatic steatosis remission in elderly patients with metabolic alcohol-associated liver disease (MetALD): a retrospective cohort study.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to determine the independent and interactive effects of changes in alcohol intake and body weight on hepatic steatosis remission in elderly patients with Metabolic Alcohol-associated Liver Disease (MetALD).
methodsThis population-based retrospective cohort study included 46,570 elderly individuals (≥65 years) with MetALD in Zhejiang Province, China (2021-2023). Changes in alcohol consumption and body weight were assessed. The primary outcome was remission of hepatic steatosis. Multivariable logistic regression was used to evaluate the associations between hepatic steatosis remission and changes in weight and alcohol consumption, with adjustment for potential confounders. Interaction effects between weight loss and alcohol reduction were also assessed.
resultsOver two years, 12.43% (n = 5789) achieved >5% weight loss, and 2.54% (n = 1181) achieved alcohol cessation. The overall remission rate for hepatic steatosis was 22.64% (n = 10,543). Weight loss was the primary driver: remission rates were 34.34% for >5% loss (Odds ratios 2.15, 95% confidence interval [CI] 1.99-2.32) and 24.07% for 1-5% loss (1.26, [1.18-1.34]). Weight gain >5% was associated with lower remission likelihood (0.67, [0.61-0.74]). Compared with the stable consumption group, neither alcohol reduction (1.02, [0.96-1.08]) nor cessation (1.13, [0.98-1.29]) alone was significantly associated with increased remission likelihood, whereas increased consumption was associated with decreased likelihood (0.83, [0.78-0.89]). Notably, a supra-additive synergistic interaction was observed between weight loss (>1%) and alcohol reduction (including cessation) (1.88, [1.74-2.03]). The remission rate reached 37.66% (2.67, [1.69-4.29]) in the alcohol cessation group with >5% weight loss.
conclusionIn elderly patients with MetALD, weight loss >5% is strongly correlated with hepatic steatosis remission, while alcohol reduction exhibits a supra-additive synergistic association with weight loss for steatosis improvement. Clinical strategies should prioritize weight loss of 1-5%-a feasible and safe target in older adults-alongside alcohol reduction, as this combination is associated with optimized clinical outcomes.
Identifiers
42420602What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.